| Article Author and Date | Article Title | Research Question(s) | Research Design / Type | Setting, Sample, Inclusion / Exclusion Criteria | Methods, Interventions, and/or Instruments | Analysis(es) | Key Results | Recommendations |
|---|---|---|---|---|---|---|---|---|
| 2024 |
Lithium, the gold standard drug for bipolar disorder: analysis of current clinical studies
|
Why is lithium still considered the gold standard to treat bipolar disorder? | Qualitative synthesis | Multicenter clinical trials and observational studies in healthcare settings. Sample included adults with bipolar disorder. Included studies focused on treatment of bipolar disorder with lithium. Excluded studies where lithium was not used in treating bipolar disorder. | Review of published clinical trial data. Lithium used as monotherapy and in combination with other psychotropic medications. Standard clinical outcome measures included relapse rate and mood rating. | Comparative and thematic analyses of findings across multiple studies. | Lithium remains the number one treatment in preventing manic and depressive episodes of bipolar disorder. It shows efficacy in reducing suicide risk in patients with manic depression. Side effects, if monitored, are not severe. | Use lithium in patients diagnosed with manic depression. Educate clinicians on monitoring and managing lithium and its side effects. |
| 2023 |
Facts and myths about the use of lithium for bipolar disorder in routine clinical practice: an expert consensus paper
|
What are the facts and misconceptions about the use of lithium in everyday clinical practice, and what reasons support its use in treating bipolar disorder? | Narrative literature review and expert consensus | General clinical practice setting. Adult patients with bipolar disorder. Included publications addressing efficacy, monitoring, and safety of lithium in clinical practice. No specific exclusion criteria noted due to the narrative nature of the review. | Narrative search using keywords such as lithium, bipolar, and myth. Coverage of lithium in several formulations. Expert judgement and synthesis of clinical evidence. | Qualitative appraisal identifying myths such as unmanageable drug interactions and contrasting them with identified benefits. | The article highlights myths and reveals that lithium should be first-line treatment, drug interactions are manageable, and dose adjustment should be routinely monitored. | Lithium efficacy and safety information should be more widely known. Routine labs and monitoring should be emphasized. |
| 2022 |
Lithium Treatment of Bipolar Disorder in Adults: A Systematic Review of Randomized Trials and Meta Analysis
|
Using RCTs and meta-analysis, how strong is the evidence for using lithium in treating bipolar disorder in adults? | Systematic review (RCTs, meta-analyses, post hoc analysis) using PRISMA guidelines | International clinical trial settings and observational studies covering manic depression and acute mania in adults with bipolar disorder. Included English RCTs, meta-analyses, and post-hoc analyses evaluating adults treated with lithium. Excluded non-English and non-randomized studies. | Systematic review of RCTs and meta-analyses using PRISMA. Used validated scales, with MEDLINE search terms such as mania, bipolar, and randomized. Lithium used as monotherapy or adjunctive therapy. Instruments included standardized scales such as YMRS. | Mixed methods, including both quantitative and qualitative synthesis. The review relied on validity and reliability of measures established in primary clinical trials and registry databases. | Lithium monotherapy was effective in treating acute mania and was effective in acute bipolar depression when used in combination with other psychotropics. | Use lithium as first-line treatment in acute mania and as maintenance treatment of manic depression. |
| 2024 |
Lithium: Current state of the art and future directions
|
What is the current evidence-based status of lithium in treating bipolar disorder, and for what other conditions does it show use? | Comprehensive narrative review | Global clinical practice setting. Sample from RCTs and meta-analyses. Included high-quality studies on efficacy and safety of lithium. Old and unrelated studies were excluded. | Literature synthesis of clinical trials and meta-analyses. Standard lithium therapy with serum lithium, renal, and thyroid function monitoring. Clinical outcome scales were reviewed. | Qualitative analysis | Lithium remains highly effective in treating mania and as maintenance therapy. Rate of toxicity is fairly low. Renal function monitoring is required although renal impairment remains low. | Utilize lithium as a first-line treatment in acute mania and maintenance of bipolar disorder. |
| 2023 |
Beyond its psychiatric use: the benefits of low-dose lithium supplementation
|
What are the benefits of low-dose lithium (< 0.5 serum level) use in non-psychiatric conditions? | Narrative review | Review of studies of dietary supplements in animals and humans. Sample included healthy volunteers, animal models, and older adults. Included studies examining lithium serum level of less than or equal to 0.5mM. Excluded studies with serum lithium level greater than or equal to 0.5mM. | Systematic literature search using low-dose lithium as a dietary supplement. Functional assays, biomarkers, clinical outcomes, and inflammatory markers were used. | Qualitative analysis | Low-dose supplemental lithium produced health benefits including metabolic, cardiovascular, and musculoskeletal benefits. | Clinical trials should be conducted to examine long-term impact on metabolic health. |
| 2022 |
The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression
|
Does lithium treatment reduce comorbid anxiety symptoms in patients with bipolar depression? | 6-week clinical trial | Clinical trial conducted in one psychiatric clinic sampling 31 adults diagnosed with manic depression. Included adults diagnosed with bipolar depression and anxiety who were able to give consent. Exclusion included use of other psychotropic medications not specified in the study. | Lithium monotherapy titrated to low serum levels. Depression symptoms measured using HAM-D and anxiety symptoms using HAM-A scales. | Compared baseline vs. 6-week HAM-D and HAM-A scores. | Therapeutic effect with low serum levels of lithium. Reduction in HAM-D and HAM-A scores indicated improvement in depression and anxiety. | Low-dose lithium may be useful in treating depression with comorbid anxiety. Larger controlled studies are needed. |
| 2022 |
Study of bipolar treatment finds lithium linked to better outcomes
|
Does long-term treatment with lithium lead to better outcomes? | Narrative literature review | Adult population in outpatient and inpatient settings globally. Sample involved RCTs comparing lithium with placebo or other mood stabilizers. Included adults diagnosed with bipolar disorder receiving lithium monotherapy or adjunctive lithium therapy. Excluded non-bipolar, pediatric, and non-adult populations. | Literature review of existing trials, meta-analyses, and cohort studies. Compared lithium, lamotrigine, antipsychotics, and placebo. Outcomes included mood relapse, psychiatric hospitalization, and metabolic changes. | Comparison of outcome rates across therapeutic groups from RCT and cohort data. | Lithium showed significant relapse prevention compared to placebo and other mood stabilizers. Weight gain with lithium was less than with other drugs. | Lithium should remain first-line treatment for adults with bipolar disorder. Providers should actively address lithium myths. |
| 2024 |
Why is lithium (not) the drug of choice for bipolar disorder? A controversy between science and clinical practice
|
Why has lithium use decreased in clinical practice despite being the most scientifically supported therapy for bipolar disorder, and how can the gap between routine care and research be addressed? | Narrative literature review synthesizing evidence from clinical trials, national registry data, and observational studies | Global bipolar disorder treatment settings using mental health registries, outpatient and inpatient services. Adult population with bipolar disorder treated with lithium or alternative medications. Included studies on lithium’s acute, depressive, prescription trend, and monitoring issues. Excluded non-bipolar diagnoses and pediatric populations. | RCT reviews, health system interventions, and meta-analyses. Compared lithium in acute mania, depression, and maintenance phases with placebo and antipsychotics. Outcomes included relapse, mood episodes, suicide, and self-harm rates. | Qualitative review, comparative analysis, descriptive review. | Lithium use has decreased in recent years, yet it remains most effective for acute mania and mood stabilization. | Lithium should be used as first-line therapy for maintenance in bipolar disorder. Myths should be addressed and provider/patient education improved. |
| 2022 |
Lithium in the treatment of acute bipolar depression: A systematic review and meta analysis
|
Does lithium treatment improve response rates in acute bipolar depression compared to placebo or antidepressants? | Systematic review and meta-analysis of RCTs | Clinical trials in inpatient and outpatient psychiatric settings involving 17 studies with 1,545 participants. Included trials comparing lithium use in bipolar vs. unipolar depression. Excluded non-controlled designs and studies lacking response rate data. | Systematic literature search using PICOS criteria and data extraction. Lithium monotherapy in acute bipolar depression. Response defined as >50% decrease in depressive symptoms. Underlying studies likely used validated scales such as MADRS and HAM-D. | Meta-analytic pooling of response rates across studies comparing lithium vs. antidepressants and lithium vs. placebo. No direct validity or reliability testing of scales was performed in the review. | Lithium was numerically worse than antidepressants but not statistically significant. Lithium was numerically better than placebo but also not statistically significant. | Larger, more rigorous RCTs using remission outcomes are needed to clarify lithium’s efficacy. |
| 2023 |
Lithium in bipolar depression: A review of the evidence
|
What is the current clinical evidence regarding the efficacy of lithium in treating acute bipolar depression, and what gaps exist to guide future research? | Systematic review following PRISMA guidelines | Clinical trials across inpatient and outpatient settings involving 15 studies of patients diagnosed with bipolar depression. Included clinical studies examining lithium in bipolar depression. Excluded non-controlled studies, non-bipolar populations, and pediatric populations. | Systematic database searches in PubMed, PsycINFO, and Embase using keywords including lithium, bipolar depression, and dosage. Measures were mainly response rates; scales were not consistently reported. | Narrative synthesis of clinical outcomes across 15 studies. No meta-analysis was performed. No new validity or reliability assessments were made. | No RCTs used therapeutic lithium concentrations with placebo control. Only low-quality and limited evidence supports lithium efficacy in acute bipolar depression. | There is urgent need for rigorous trials with appropriate dosing, monitoring, and clinical outcome measures. |
| 2022 |
Why lithium should be used in patients with bipolar disorder? A scoping review and an expert opinion paper
|
Why should lithium be used in patients with bipolar disorder? | Scoping review / knowledge synthesis and expert opinion | Clinical and real-world settings focusing on adult populations with bipolar disorder. Included studies and clinical data related to use of lithium in adults. Pediatric population excluded. | Scoping review of evidence related to side effects, dosing, efficacy, switching strategies, and formulations of lithium therapy. | Qualitative synthesis of literature with expert commentary focusing on efficacy in prevention of recurrence and management of side effects. | Clinical use of lithium has declined over the past 20–30 years. Side effects are manageable. Lithium is effective in treating bipolar disorder. | Encourage wider use of lithium as a first-line, gold-standard mood stabilizer in everyday clinical settings. Consider slow-release formulations to offset side effects. |
| 2022 |
Therapeutic application of lithium in bipolar disorders: A brief review
|
What are the therapeutic benefits of lithium, mechanisms of action, adverse effects, and its clinical role in treating bipolar disorder? | Narrative review | Global scope including low- to high-income country studies and community mental health centers. Adult population with bipolar depression. Included studies on lithium in bipolar disorder and adverse reactions. | Electronic database searches using keywords such as bipolar disease, therapeutics, psychotherapy, and lithium. Reviewed lithium monotherapy and combination therapy, relapse prevention, and mood stabilization outcomes. | Qualitative narrative integration of clinical and basic science findings. No formal meta-analysis or quantitative reliability assessments due to narrative scope. | Lithium is effective for mood stabilization and relapse prevention, especially when combined with psychotherapy. Adverse cognitive effects seem less significant in patients with bipolar disorder than in healthy subjects. Monitoring is needed for metabolic effects. | Use lithium as a first-line mood stabilizer alongside psychotherapy. Monitor serum lithium, renal, and thyroid function regularly. Support public health programs combining lithium therapy with psychotherapy. |
| 2020 |
Lithium treatment over the lifespan in bipolar disorders
|
How does lithium perform in managing bipolar disorder across the lifespan, and what is its impact on mood episodes, suicidality, and long-term adverse effects? | Narrative literature review | Global clinical environments including inpatient and outpatient units. Sample included individuals from childhood to older adulthood with bipolar disorder. Included studies on efficacy in acute mania, bipolar depression, suicidal prevention, and adverse outcomes. Excluded non-bipolar or non-lithium studies. | Review of clinical and pharmacological studies including guidelines and meta-analyses. Lithium used in acute treatment and maintenance. Standard scales included YMRS, MADRS, CGI, and Morbidity Index. | Qualitative synthesis comparing efficacy, safety profiles, and benefit-risk ratio across life stages. No new statistical testing performed in the review. | Lithium is effective as first-line treatment in acute mania and maintenance in bipolar disorder. Its anti-suicidal effect is highlighted, including zero suicides in RCT lithium arms versus placebo-associated deaths. | Adopt lithium as first-line treatment of mania and maintenance across the lifespan. Ensure proper pediatric dosing and monitoring of serum lithium, renal, and thyroid functions. Future research should investigate long-term cognitive and physical health impact. |